has announced May 12 as the date of a highly anticipated US Food and Drug Administration鈥檚 (FDA) Advisory Committee meeting to consider the approval of its SRP-9001
For Sarepta, the is in contrast to the that review of SRP-9001 would take place without an advisory committee. However, more recently on March 16, the company announced the FDA鈥檚 plan to hold an advisory committee meeting before its PDUFA date of May 29. At the time, the company鈥檚 CEO Doug Ingram said, 鈥淚t is our understanding that as one of the first gene therapy BLAs founded on a surrogate endpoint, the advisory committee will primarily relate to the totality of evidence supporting the conclusion that the SRP 9001 dystrophin is reasonably likely to predict clinical benefit, the standard for accelerated approval.鈥�.
The company鈥檚 shares fell by 20% at market opening after the March 16 announcement. Although the stock price has partially recovered, eyes will be on the FDA advisory committee meeting鈥檚 outcome to see whether future turbulence awaits Sarepta.
The apparent tightening of approval scrutiny around surrogate endpoints is at the center of the tension around the potential approval of SRP-9001, also known as delandistrogene moxeparvovec. The Phase III ENDEAVOR study, which is part of the SRP-9001’s BLA package, used a primary endpoint centered on measuring micro-dystrophin expression, a surrogate marker that has been used in the regulatory approvals for exon-skipping therapies.
In light of the confirmed date for the advisory committee, Ingram said 鈥渨e look forward to sharing the wealth of evidence supporting the transformative potential of SRP-9001 for the treatment of Duchenne muscular dystrophy鈥�.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEditorial content is independently produced and follows the of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
